Executive record
Bernhardt G. Zeiher
Public governance roles and source-backed Claims for this individual.
More
Alpha ID: alpha:person:bernhardt-g-zeiherVersion: public-0As of: 2026-10-05
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
- Executive titleExecutive title: DirectorABEO DEF 14A executive officers
- AI and ML experienceAI and ML experience: not identified in the cited filingABEO DEF 14A executive officers
- Cybersecurity experienceCybersecurity experience: not identified in the cited filingABEO DEF 14A executive officers
- Executive companyExecutive at ABEONA THERAPEUTICS INC.ABEO DEF 14A executive officers
Biography
Became director in August 2024. Over 20 years of drug development experience overseeing approval of 15 new treatments. Most recently Chief Medical Officer of Astellas Pharma (2018-2022). Previously held drug development roles at Pfizer, Eli Lilly, and Merck. Also serves on board of Entrada Therapeutics and Amylyx Pharmaceuticals.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Board service coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageExecutive career
- 2026 to end not publishedExecutive title: Director · Organization not publishedABEO DEF 14A executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
ABEO DEF 14A executive officers
sec filing · Source published: Apr 27, 2026 · Retrieved: May 15, 2026
Supports 6 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Executive company: Executive at ABEONA THERAPEUTICS INC. · Claim reviewed: May 15, 2026
- Executive title: Executive title: Director · Claim reviewed: May 15, 2026
- Other Company Role: Bernhardt G. Zeiher is also linked to Amylyx Pharmaceuticals, Inc. as Board Member. · Claim reviewed: May 15, 2026
- Technology background: Technology background reported in filings · Claim reviewed: May 15, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-05
- Biography
- published
- Board service
- not observed
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope